On RemeGen (688331.SH/09995.HK) announced that the results of the Phase III clinical study of Telitacicept for Sjögren's Syndrome in China have been published in an abstract on the 2025 ACR website.
The authors describe an interesting approach to studying the dynamics and function of membrane proteins in different lipid environments. The important findings have theoretical and practical ...
AlphaFold 3 (AF3), the latest AI model from Google DeepMind and Isomorphic Labs, can predict the structures and interactions ...
Pharma companies are collaborating to boost the power of artificial intelligence (AI) in drug discovery by allowing access to ...
News-Medical.Net on MSN
New AI system revolutionizes drug design and vaccine development
The rapid advancement of artificial intelligence (AI) is transforming the field of structural biology. In May 2024, DeepMind and Isomorphic Labs launched AlphaFold 3 (AF3), a revolutionary AI system ...
Discover how integrating artificial intelligence with biophysical methods enables the identification of novel BRPF1b ...
Researchers have discovered how unstructured segments of surface proteins regulate the biological function of a cell. Their ...
A landmark study published in Experimental Neurology demonstrates that Polku Therapeutics' proprietary prolyl oligopeptidase (PREP) ligand prevents long-term memory impairment in a model of repeated ...
The AI Structural Biology (AISB) consortium was set up earlier this year to fine-tune OpenFold3, which is being developed by ...
Takeda Pharmaceuticals and Astex Pharmaceuticals are the latest companies to join the AI Structural Biology (AISB) Network, a ...
SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback